title: Second-Line Therapy for Endometrial Cancer: The Need for Better Options.
authors.affiliation: University of Chicago, Chicago, IL gfleming@medicine.bsd.uchicago.edu.
authors.forename: Gini F
authors.initials: GF
authors.lastname: Fleming
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy / Q000532:radiotherapy; D000588:Amines / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D016889:Endometrial Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D047628:Estrogen Receptor alpha / Q000378:metabolism; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D000077206:Gabapentin; D006801:Humans; D008495:Medical Oncology / Q000379:methods; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D011980:Receptors, Progesterone / Q000378:metabolism; D012004:Rectal Neoplasms / Q000150:complications / Q000188:drug therapy / Q000532:radiotherapy; D020521:Stroke / Q000150:complications; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
chemical_list: D000588:Amines; D003509:Cyclohexanecarboxylic Acids; C506487:ESR1 protein, human; D047628:Estrogen Receptor alpha; D011980:Receptors, Progesterone; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D016190:Carboplatin; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D017239:Paclitaxel; D005472:Fluorouracil